

CREATION OF A PEDAGOGICAL TOOL TO OPTIMIZE THE VALIDATION OF CHEMOTHERAPIES RELATED TO RHABDOMYOSARCOMA

PERNA F^{1,3}, UDA ME², ANNEREAU M³, ABOUDAGGA H³, RIEUTORD A³, VO N³

1. Hospital Pharmacy School, University *La Sapienza*, Roma, Italy


2. Hospital Pharmacy School, University of Sassari, Sassari, Italy

3. Gustave Roussy Cancer Campus, Villejuif, France

Why was it done?



How was it done?



What has been achieved?


1 Systematic review

- 2 tools found
- None regarding pharmaceutical validations



Literature analysis : different pedagogical strategies

Radar chart regarding the pedagogical approaches



2 Feedback from hospitals

- 17 hospitals contacted
- 6 French hospitals
 - 10 European hospitals
 - 1 Canadian hospital
 - 9 responses with datas

→ no pedagogical tool found
 → formation based on :
 reading SOPs and working alongside a senior pharmacist

GUIDE DE VALIDATION EN ONCOLOGIE
 POUR LE PHARMACIEN:
 RHABDOMYOSARCOME



Pedagogical tool

in paper and pdf format created according to GR pharmacists needs

TRAITEMENT DES PATIENTS À RISQUE STANDARD SOUS-GROUPE D

Traitement

- ✓ Ifosfamide (I) 3 g/m² i.v. perfusion de 3h avec mesna 3 g/m² et hydratation
- ✓ Vincristine (V) 1,5 mg/m² (dose max 2 mg) i.v.
- ✓ Actinomycine D (A) 1,5 mg/m² (dose max 2 mg) i.v.
- ✓ L'intervalle entre les cures est de 3 semaines
- ✓ Pour les enfants de < 1 mois, seul l'AV doit être administré au 1er cycle.


Bilan biologiques à vérifier

- PNN: 1 x 10³/L
- Plaquettes: 80 x 10³/L
- Absence de dysfonctionnement de coeur, foie et rein.
- Administration indépendant de la pancytopenie


Pour les enfants < 1 an (ou < 10 kg de poids corporel) voir page ...

3 Answers of the need's questionnaire

NEED EXPRESSED BY THE PHARMACISTS



PREFERENCES RELATED THE TOOL FORMAT



What 's next?

The future prospect would be to **develop other tools to support pharmaceutical validation** so that we can invest more and more and provide more and more **quality training to new hospital pharmacists.**

